Log in

Relevant bibliographies by topics / SEER database / Journal articles

To see the other types of publications on this topic, follow the link: SEER database.

Journal articles on the topic 'SEER database'

Author: Grafiati

Published: 25 May 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'SEER database.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Ayman, Rasmy, Ameen Amal, and AbdMonem Amira. "Lung Cancer Treatment: Incidence and Survival: SEER Database." Cancer Medicine Journal 2, no. 2 (December 31, 2019): 36–40. http://dx.doi.org/10.46619/cmj.2019.2-1011.

Full text

Abstract:

Lung cancer is the most common cause of cancer death worldwide, with an estimated 1.6 million deaths each year. Nearly 85% of cases have a different histological groups jointly recognized as “Non-Small Cell Lung Cancer of which lung adenocarcinoma and lung squamous cell carcinoma are the most common subtypes”.

APA, Harvard, Vancouver, ISO, and other styles

2

Aytekin, Mahmut Nedim, Recep Öztürk, Mehmet Atıf Erol Aksekili, Ercan Bal, and Metin Doğan. "Clear cell chondrosarcoma: SEER database analysis." Acta Oncologica Turcica 53, no. 1 (2020): 24–28. http://dx.doi.org/10.5505/aot.2020.04382.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Chandana, Sreenivasa Rao, and Chintan Shah. "Appendiceal adenocarcinoma: Analysis of SEER database." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): e18097-e18097. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e18097.

Full text

Abstract:

e18097 Background: Appediceal cancers (AC) are rare, and often found on appendectomies. Adenocarcinomas represents approximately two-thirds of all AC. We performed the analysis of SEER database to understand the overall incidence and survival trends. Methods: We analyzed SEER database: Incidence - SEER 18 RegsResearch Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2015 Sub (1973-2013 varying). Cases diagnosed of AC between 1988 and 2013 were identified. Trend of incidence rate was calculated. Relative survival rates (RSR) were calculated stratified by age, gender, race, stage, histological subtypes which were divided into mucinous, non-mucinous and signet ring cell carcinoma (SRCC). We calculated survival difference for patient diagnosed before and after 2000. Results: Age adjusted incidence rate of appendiceal adenocarcinoma was 0.4 cases per 100,000 person years. Overall incidence rate increased on average 3.7% per 100,000 person years (P < 0.05). The highest increase was seen in SRCC (4.8% per 100,000 person years). Survival was worst in SRCC (5 years RSR-28.40%) compared to other types (5 year RSR- 61.0% and 52.90% for mucinous and non-mucinous carcinoma (P < 0.01). Survival significantly improved for patients diagnosed after 2000 for mucinous (5 years RSR -51.90% and 64.30%) and SRCC (5 year RSR-18.0% and 31.0%), respectively before and after 2000 in each category. No improvement in survival was found in non-mucinous carcinomas since 2000. While survival among different histological types was not different for localized disease, it was significantly better for regional or distant stages in mucinous cancers when compared to non-mucinous cancers (P < 0.01). Elderly patient ( > 65 years) showed significantly poor survival for mucinous and non-mucinous carcinomas, while there was no variation in survival based on age for SRCC. Moreover, females showed significantly poor survival (P < 0.05) compared to males for SRCC, while no variation in survival based on gender for other types. Survival was not different among different races. Conclusions: Incidence of appendiceal adenocarcinomas is increasing. The highest increase is seen in SRCC which has the worst survival. Survival from mucinous adenocarcinomas has improved significantly in last decade.

APA, Harvard, Vancouver, ISO, and other styles

4

Fiellin, Martha, Susan Chemerynski, and Jonathan Borak. "Race, ethnicity, and the Seer database." Medical and Pediatric Oncology 41, no. 5 (September 22, 2003): 413–14. http://dx.doi.org/10.1002/mpo.10400.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Oh, Janice, Yazan Abboud, Miguel Burch, Jun Gong, Kevin Waters, Jenan Ghaith, Yi Jiang, et al. "Rising Incidence of Non-Cardia Gastric Cancer among Young Women in the United States, 2000–2018: A Time-Trend Analysis Using the USCS Database." Cancers 15, no. 8 (April 13, 2023): 2283. http://dx.doi.org/10.3390/cancers15082283.

Full text

Abstract:

Introduction: Although the global incidence of non-cardia gastric cancer (NCGC) is decreasing, there are limited data on sex-specific incidence in the United States. This study aimed to investigate time trends of NCGC from the SEER database to externally validate findings in a SEER-independent national database, and to further assess trends among subpopulations. Methods: Age-adjusted incidence rates of NCGC were obtained from the SEER database from 2000 to 2018. We used joinpoint models to calculate average annual percentage change (AAPC) to determine sex-specific trends among older (≥55 years) and younger adults (15–54 years). Using the same methodology, findings were then externally validated using SEER-independent data from the National Program of Cancer Registries (NPCR). Stratified analyses by race, histopathology, and staging at diagnosis were also conducted in younger adults. Results: Overall, there were 169,828 diagnoses of NCGC from both independent databases during the period 2000–2018. In SEER, among those <55 years, incidence increased at a higher rate in women (AAPC = 3.22%, p < 0.01) than men (AAPC = 1.51%, p = 0.03), with non-parallel trends (p = 0.02), while a decreasing trend was seen in both men (AAPC = −2.16%, p < 0.01) and women (AAPC = −1.37%, p < 0.01) of the ≥55 years group. Validation analysis of the SEER-independent NPCR database from 2001 to 2018 showed similar findings. Further stratified analyses showed that incidence is disproportionately increasing in young non-Hispanic White women [AAPC = 2.28%, p < 0.01] while remaining stable in their counterpart men [AAPC = 0.58%, p = 0.24] with non-parallel trends (p = 0.04). This pattern was not observed in other race groups. Conclusion: NCGC incidence has been increasing at a greater rate in younger women compared to counterpart men. This disproportionate increase was mainly seen in young non-Hispanic White women. Future studies should investigate the etiologies of these trends.

APA, Harvard, Vancouver, ISO, and other styles

6

Ramsingh, G., P. Mehan, J. Luo, R. Vij, and D. Morgensztern. "Plasma cell leukemia: A SEER database analysis." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): 8605. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.8605.

Full text

Abstract:

8605 Background: Primary plasma cell leukemia (PCL) is a rare plasma cell disorder with clinical information limited to small series of patients. Methods: We analyzed the Surveillance Epidemiology and End Results (SEER) database to evaluate the patient characteristic and survival data for patients with PCL. Patients were divided into cohorts based upon age, gender, race and time period of diagnosis. Kaplan-Meier product limit method was used to estimate survival functions for group in each risk factor. Demographics and survival over different periods of time from 1973 and 2004 were compared with multiple myeloma. Results: Among the 291 patients with PCL, median age was 67 years (range 19–98), and the male/female distribution was equal and the most common race was white (79.4%). Median overall survival (OS) and disease specific survivals (DSS, defined by interval from diagnosis to the event of death from PCL) were 4 months and 6 months respectively. The 1 year, 2 year and 5 year overall survival rates were 22.7%, 10.2% and 3.8% respectively. The survival did not differ between gender and race. Patients ≤60 years had a better median overall survival compared to older patients (median OS: 7 months Vs 3 months, p=0.007), although 5-year overall survival was equally poor for either group (6.9% Vs 6.7%). During the same period, we identified 49,106 patients with MM. Demographics for MM showed a slightly increased median age of 70 years, but similar race and gender distribution. Unlike MM, where there has been a modest but statistically significant survival improvement over time, both OS and DSS remained stable in PCL ( Table ). Conclusions: This is the largest study to analyze demographic and survival data on patients with PCL. The poor long term outcome and the lack of improvement in survival of patients with PCL despite small gains in MM suggest a more aggressive disease, for which further therapeutic agents are needed. [Table: see text] No significant financial relationships to disclose.

APA, Harvard, Vancouver, ISO, and other styles

7

Acharya, Pankti P., Deeksha Sarma, and Brian McKinnon. "Trends of temporal bone cancer: SEER database." American Journal of Otolaryngology 41, no. 1 (January 2020): 102297. http://dx.doi.org/10.1016/j.amjoto.2019.102297.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Edwards, George, Lucas Ashley, Arjun Bhatt, and Aidan Burke. "PENILE SQUAMOUS CELL CARCINOMA SEER DATABASE ANALYSIS." Urologic Oncology: Seminars and Original Investigations 42 (March 2024): S67. http://dx.doi.org/10.1016/j.urolonc.2024.01.193.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Lin, Min-Qiang, Chen-Lu Lian, Ping Zhou, Jian Lei, Jun Wang, Li Hua, Juan Zhou, and San-Gang Wu. "Analysis of the Trends in Publications on Clinical Cancer Research in Mainland China from the Surveillance, Epidemiology, and End Results (SEER) Database: Bibliometric Study." JMIR Medical Informatics 8, no. 11 (November 17, 2020): e21931. http://dx.doi.org/10.2196/21931.

Full text

Abstract:

Background The application of China’s big data sector in cancer research is just the beginning. In recent decades, more and more Chinese scholars have used the Surveillance, Epidemiology, and End Results (SEER) database for clinical cancer research. A comprehensive bibliometric study is required to analyze the tendency of Chinese scholars to utilize the SEER database for clinical cancer research and provide a reference for the future of big data analytics. Objective Our study aimed to assess the trend of publications on clinical cancer research in mainland China from the SEER database. Methods We performed a PubMed search to identify papers published with data from the SEER database in mainland China until August 31, 2020. Results A total of 1566 papers utilizing the SEER database that were authored by investigators in mainland China were identified. Over the past years, significant growth in studies based on the SEER database was observed (P<.001). The top 5 research topics were breast cancer (213/1566, 13.6%), followed by colorectal cancer (185/1566, 11.8%), lung cancer (179/1566, 11.4%), gastrointestinal cancer (excluding colorectal cancer; 149/1566, 9.5%), and genital system cancer (93/1566, 5.9%). Approximately 75.2% (1178/1566) of papers were published from the eastern coastal region of China, and Fudan University Shanghai Cancer Center (Shanghai, China) was the most active organization. Overall, 267 journals were analyzed in this study, of which Oncotarget was the most contributing journal (136/267, 50.9%). Of the 1566 papers studied, 585 (37.4%) were published in the second quartile, 489 (31.2%) in the third quartile, 312 (19.9%) in the first quartile, and 80 (5.1%) in the fourth quartile, with 100 (6.4%) having an unknown Journal Citation Reports ranking. Conclusions Clinical cancer research based on the SEER database in mainland China underwent constant and rapid growth during recent years. High-quality and comprehensive cancer databases based on Chinese demographic data are urgently needed.

APA, Harvard, Vancouver, ISO, and other styles

10

Janz, Tyler A., Evan M. Graboyes, Shaun A. Nguyen, Mark A. Ellis, David M. Neskey, E. Emily Harruff, and Eric J. Lentsch. "A Comparison of the NCDB and SEER Database for Research Involving Head and Neck Cancer." Otolaryngology–Head and Neck Surgery 160, no. 2 (August 21, 2018): 284–94. http://dx.doi.org/10.1177/0194599818792205.

Full text

Abstract:

Objective To determine whether structural differences in data sampling between the National Cancer Database (NCDB), a non-population-based cancer registry, and Surveillance, Epidemiology, and End Results (SEER), a population-based cancer registry, result in differences in patient characteristics or oncologic outcomes. Study Design Retrospective cohort study. Setting NCDB and SEER database. Subjects and Methods Patients with head and neck cancer (HNC) were included from 2004 to 2014. The primary outcome, weighted differences in characteristics between the databases, was evaluated for each head and neck subsite (oral cavity [OC], oropharynx [OP], hypopharynx [HP], and larynx [LX]). The secondary outcome measure, overall survival (OS), was evaluated using Kaplan-Meier (KM) estimates of survival and Cox proportional hazards (PH) regression modeling. Results In total, 112,007 and 340,420 HNC cases were registered in SEER and the NCDB, respectively. The mean age at diagnosis for the 4 head and neck subsites differed by no more than 1.1 years between the 2 databases. The largest difference in patient or tumor characteristics was the frequency of OC subsite lip cancer (weighted proportional difference, 6.9%; 95% confidence interval, 6.5%-7.3%). Unadjusted KM estimates of 5-year OS differed by no more than 2% (OP, HP, and LX subsites). On Cox PH modeling, adjusted hazard ratios ranged from 0.89 to 0.91 for patients of different head and neck subsites in the NCDB relative to SEER. Conclusions Patients with HNC in the SEER database and NCDB do not greatly differ in terms of demographics, treatment, and survival. Decisions to use either database should be driven by the data fields, which vary between the registries.

APA, Harvard, Vancouver, ISO, and other styles

11

Leopold, Zev, Priya Dave, Adarsh Menon, Hiren V. Patel, Arnav Srivastava, Isaac Yi Kim, Thomas L. Jang, and Eric A. Singer. "Trends in the use of administrative databases in urologic oncology: 2000 – 2019." Journal of Clinical Oncology 39, no. 6_suppl (February 20, 2021): 356. http://dx.doi.org/10.1200/jco.2021.39.6_suppl.356.

Full text

Abstract:

356 Background: Administrative databases (AD) provide investigators with nationally representative study populations to answer research questions using large sample sizes. We aimed to quantify the trends and incidence of AD use in published manuscripts in urologic oncology. We examined six commonly used databases: National Cancer Database (NCDB), Surveillance, Epidemiology and End Results Database (SEER), SEER-Medicare (SEER-M), Nationwide Inpatient Sample (NIS), National Surgical Quality Improvement Program (NSQIP), and Premier Healthcare Database (PHD). Methods: A literature review powered by PubMed and DistillerSR from 7/1/2000 to 6/30/2019 aggregated manuscripts that used the aforementioned databases to study a genitourinary malignancy. Included publications were categorized by database used, corresponding author department affiliation, organ, journal, year, and contribution – defined as temporal treatment trends, outcomes and survival, comparative effectiveness research, or cost-effectiveness. Results: There were 2,265 publications across 302 journals that met the inclusion criteria. Between 2000 and 2019 the compound annual growth rate of these publications was 18.7%. SEER contributed most heavily over the study period, with a 14.6% growth rate. NCDB use grew 75.6% annually starting in 2012. Prostate cancer comprised the majority of publications (51.3%), followed by kidney (23.1%) and bladder (22.5%) cancer. Journals publishing these manuscripts had a median impact factor of 3.28 (IQR = 1.84 – 5.74) in 2019. Urologists published 52.5% of AD manuscripts over the study period. Conclusions: Our results show substantial growth in the use of ADs for the study of urologic oncology. Given the broad use of ADs, investigators and specialty societies should advocate for continued improvement in the data captured by them.

APA, Harvard, Vancouver, ISO, and other styles

12

Zhang, C., S. Wang, and I. Deutsch. "A SEER Database Analysis of Urethral Cancer Management." International Journal of Radiation Oncology*Biology*Physics 84, no. 3 (November 2012): S425. http://dx.doi.org/10.1016/j.ijrobp.2012.07.1124.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Muzaffar, Mahvish, Sandeep Kaur, Fir Afroz, Maqbool Lone, Nazir Ahmad Khan, and MA Teli. "Conditional survival for intrahepatic cholangiocarcinoma: SEER database analysis." Journal of Clinical Oncology 32, no. 3_suppl (January 20, 2014): 201. http://dx.doi.org/10.1200/jco.2014.32.3_suppl.201.

Full text

Abstract:

201 Background: Conditional survival can be useful for estimating survival probability for patients who have survived one or more years after the initial diagnosis. It reflects the possible change in risk profile over time especially for malignancies with poor outcome. Methods: The Surveillance, Epidemiology and End Results database was reviewed for intrahepatic cholangiocarcinoma. We reviewed data for all intrahepatic cholangiocarcinoma from year 2000-2010. Data of 8278 patients was extracted from SEER database. We sub stratified using factors like age <50 versus ≥50, gender, grade, stage, primary site surgery. SEER*Stat: Version *8.1.2 software was used to calculate conditional survival. Conditional survival is defined as the calculated probability of survival after having already survived a specified number of years from diagnosis. Results: The analysis showed that Conditional survival (CS) probability for intrahepatic cholangiocarcinoma increased from 33.25 to 85% at 5 years for all age groups conditional to surviving one year after diagnoses. For age group <50 years CS increased from 50.4% to 86.9%, while for age group >50yrs from 31.4% to 84.5%.The conditional survival for well differentiated histology increased from 60.7% to 81.0%, moderately differentiated from 53.8% to 87.7%, poorly differentiated from 37.1% to 83.6% .The conditional survival for localized stage increased from 50.7% to 88.8%, regional 40.6% to 77.7% and distant 19.0% to 65.6%.Majority of cases had missing data with regard to primary site surgery. 1707 cases had documented primary site surgery. Conditional survival for this group increased from 30.7% to 82.8% subject to surviving one year after diagnosis. Conclusions: There are several limitations associated with these results due to missing data in SEER. Nonetheless these results emphasize the trend of patient’s surviving more than 1 year after diagnosis have higher conditional survival probability. CS may provide more relevant prognostic information as compared to traditional survival estimates.

APA, Harvard, Vancouver, ISO, and other styles

14

Muzaffar, Mahvish, Sandeep Kaur, Abdul Rafeh Naqash, Sweta Jonnalagadda, and Nasreen A. Vohra. "SIDE in metastatic colon cancer: SEER Database analysis." Journal of Clinical Oncology 36, no. 4_suppl (February 1, 2018): 753. http://dx.doi.org/10.1200/jco.2018.36.4_suppl.753.

Full text

Abstract:

753 Background: Recent data suggests side of colon cancer is a prognostic factor and a potential predictive factor for biologic therapy. We sought to analyze SEER database to study impact of colon cancer side. Methods: The SEER database (version 8.3.4) was reviewed for patients with Stage IV colon cancer from 2004-2014. We only included patients with labeled primary site, and excluded appendiceal, rectal or unlabeled cases. Variables included were: age, race, gender, stage, grade and side of the tumor. Primary outcome was overall survival and disease specific survival. Cox proportional hazard regression model was employed to test the association between survival and side of cancer. Results: 48,306 patients met the inclusion criteria, median age was 67 years (range 20-108), 51% were male, and 77% patients were white. 19831 (41%) patients had left colon cancer (LCC). Right colon cancer (RCC) was associated with inferior OS and DSS compared to LCC. The median overall survival was 15 months (mo) for left side and 9 months for right colon cancer (p<0.0001). Estimated 3-year OS for RCC was 14% and 24% for LCC (p <0.0001). RCC was associated with poor outcome across different variables, among patients < 60 years of age median OS was 23 mo for LCC, and 16 mo for RCC (p .0001). In the age group ≥ 60 years, 10 mo for left side and 7 mo for RCC (p < 0.0001). Among male patients RCC had 10 mo median OS vs 16 mo for LCC (p <0.0001), women 15mo for LCC vs 9mo for RCC (<0.0001). Cox regression model suggested age (<0.001), race (<0.0001), year of diagnosis (<0.0001) and grade (<0.0001) correlate with outcome. Conclusions: Right side colon cancer is associated with poor outcome compared to left colon cancer. These findings are consistent with other recent reports.

APA, Harvard, Vancouver, ISO, and other styles

15

Al-Hussaini, Maysa, Iyad Sultan, Najyah Abuirmileh, Imad Jaradat, and Ibrahim Qaddoumi. "Pineal gland tumors: experience from the SEER database." Journal of Neuro-Oncology 94, no. 3 (April 17, 2009): 351–58. http://dx.doi.org/10.1007/s11060-009-9881-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Ramsingh, G., P. Mehn, J. Luo, D. Morgensztern, and R. Vij. "A090 Plasma Cell Leukemia: A SEER Database Analysis." Clinical Lymphoma and Myeloma 9 (February 2009): S14. http://dx.doi.org/10.1016/s1557-9190(11)70456-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Leopold, Zev, Priya Dave, Adarsh Menon, Hiren V. Patel, Arnav Srivastava, Thomas L. Jang, and Eric A. Singer. "Trends in the use of administrative databases in urologic oncology: 2000-2019." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): e17111-e17111. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e17111.

Full text

Abstract:

e17111 Background: Administrative databases (AD) provide investigators with nationally representative study populations to answer research questions using large sample sizes. Their use has significantly grown over the past 20 years, particularly in urologic oncology. We aimed to quantify the trends and incidence of AD use in published manuscripts in urologic oncology. We examined six commonly used databases: National Cancer Database (NCDB), Surveillance, Epidemiology and End Results Database (SEER), SEER-Medicare (SEER-M), Nationwide Inpatient Sample, National Surgical Quality Improvement Program, and Premier Healthcare Database. Methods: A literature review powered by PubMed and DistillerSR from 2000 to 2019 aggregated manuscripts that used the aforementioned databases to study a genitourinary malignancy. Included publications were categorized by database used, corresponding author department affiliation, organ, journal, year, and contribution - defined as temporal treatment trends, outcomes and survival, comparative effectiveness research, and cost-effectiveness. Results: There were 2265 publications across 307 journals that met the inclusion criteria. Between 2000 and 2019 the compound annual growth rate of these publications was 18.7%. SEER contributed most heavily over the study period, with a 14.6% growth rate. NCDB use grew 75.6% annually starting in 2012. Prostate cancer comprised the majority of publications (51.3%), followed by kidney (23.1%) and bladder (22.5%) cancer. Journals publishing these manuscripts had a median impact factor of 2.78 (range 0.36 - 223.68) in 2018. Urologists published 52.5% of AD manuscripts over the study period, with epidemiologists and radiation oncologists publishing 18.2% and 10.6%, respectively. Conclusions: Our results show substantial growth in the use of ADs for the study of genitourinary oncology. The increased use is likely multi-factorial and may be driven by increasing competition to secure funding, ability to answer questions previously limited by sample size, and improved quality of databases. Given the broad use of ADs, investigators and specialty societies should advocate for continued improvement in the data captured by them.

APA, Harvard, Vancouver, ISO, and other styles

18

Yoon, Tae In, Joon Jeong, Seokwon Lee, Jai Min Ryu, Young Joo Lee, Jee Yeon Lee, Ki-Tae Hwang, et al. "Survival Outcomes in Premenopausal Patients With Invasive Lobular Carcinoma." JAMA Network Open 6, no. 11 (November 8, 2023): e2342270. http://dx.doi.org/10.1001/jamanetworkopen.2023.42270.

Full text

Abstract:

ImportanceThe disparate prognostic implications between invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) have been demonstrated. However, information on premenopausal patients remains insufficient.ObjectiveTo examine long-term survival outcomes of ILC and IDC in premenopausal patients using national databases.Design, Setting, and ParticipantsThis cohort study used the Surveillance, Epidemiology, and End Results (SEER), Korean Breast Cancer Registry (KBCR), and Asan Medical Center Research (AMCR) databases to identify premenopausal patients with stage I to III ILC or IDC between January 1, 1990, and December 31, 2015. The median follow-up time was 90 (IQR, 40-151) months in the SEER database, 94 (IQR, 65-131) months in the KBCR database, and 120 (IQR, 86-164) months in the AMCR database. Data were analyzed from January 1 to May 31, 2023.Main Outcomes and MeasuresThe primary outcome was breast cancer–specific survival (BCSS), which was analyzed according to histological type, and the annual hazard rate was evaluated. Survival rates were analyzed using a log-rank test and a Cox proportional hazards regression model with time-varying coefficients. Multivariable analysis was performed by adjusting for tumor characteristics and treatment factors.ResultsA total of 225 938 women diagnosed with IDC or ILC and younger than 50 years were identified. Mean (SD) age at diagnosis was 42.7 (5.3) years in the SEER database, 41.8 (5.5) years in the KBCR database, and 41.8 (5.5) years in the AMCR database. In terms of race (available for the SEER database only), 12.4% of patients were Black, 76.1% were White, 11.0% were of other race (including American Indian or Alaska Native, Asian, and Native Hawaiian or Other Pacific Islander), and 0.5% were of unknown race). Patients with ILC had better BCSS in the first 10 years after diagnosis than those with IDC (hazard ratios [HRs], 0.73 [95% CI, 0.68-0.78] in the SEER database, 1.20 [95% CI, 0.91-1.58] in the KBCR database, and 0.50 [95% CI, 0.29-0.86] in the AMCR database), although BCSS was worse after year 10 (HRs, 1.80 [95% CI, 1.59-2.02] in the SEER database, 2.79 [95% CI, 1.32-5.88] in the KBCR database, and 2.23 [95% CI, 1.04-4.79] in the AMCR database). Similar trends were observed for hormone receptor–positive tumors (HRs, 1.55 [95% CI, 1.37-1.75] in the SEER database, 2.27 [95% CI, 1.01-5.10] in the KBCR database, and 2.12 [95% CI, 0.98-4.60] in the AMCR database). Considering the annual hazard model of BCSS, IDC events tended to decline steadily after peaking 5 years before diagnosis. However, the annual peak event of BCSS was observed 5 years after diagnosis for ILC, which subsequently remained constant.Conclusions and RelevanceThese findings suggest that premenopausal women with ILC have worse BCSS estimates than those with IDC, which can be attributed to a higher late recurrence rate of ILC than that of IDC. Histological subtypes should be considered when determining the type and duration of endocrine therapy in premenopausal women.

APA, Harvard, Vancouver, ISO, and other styles

19

Daly, Meghan, and Ian Paquette. "Surveillance, Epidemiology, and End Results (SEER) and SEER-Medicare Databases: Use in Clinical Research for Improving Colorectal Cancer Outcomes." Clinics in Colon and Rectal Surgery 32, no. 01 (January 2019): 061–68. http://dx.doi.org/10.1055/s-0038-1673355.

Full text

Abstract:

AbstractThe Surveillance, Epidemiology, and End Results (SEER) program is a clinical database, funded by the National Cancer Institute (NCI), which was created to collect cancer incidence, prevalence, and survival data from U.S. cancer registries. By capturing approximately 30% of the U.S. population, it serves as a powerful resource for researchers focused on understanding the natural history of colorectal cancer and improvement in patient care. The linked SEER-Medicare database is a robust database allowing investigators to perform studies focusing on health disparities, quality of care, and cost of treatment in oncologic disease. Since its infancy in the early 1970s, the database has been utilized for thousands of studies resulting in novel publications that have shaped our management of colorectal cancer among other malignancies.

APA, Harvard, Vancouver, ISO, and other styles

20

Choi, M., C. D. Fuller, C. R. Thomas, and S. J. Wang. "Conditional survival in ovarian cancer: A SEER database analysis." Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 6620. http://dx.doi.org/10.1200/jco.2008.26.15_suppl.6620.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Sekhar, Jeevan, Daniel Morgensztern, Qin Zhang, and Ravi Vij. "Waldenstrom's Macroglobulinemia: A SEER Database Review From 1981-2005." Blood 114, no. 22 (November 20, 2009): 2926. http://dx.doi.org/10.1182/blood.v114.22.2926.2926.

Full text

Abstract:

Abstract Abstract 2926 Poster Board II-902 Introduction: Waldenstrom's Macroglobulinemia (WM) is a relatively rare hematopoietic neoplasm, with literature data mostly limited to small series of patients. We conducted a review of the Surveillance Epidemiology and End Results (SEER) database for WM analyzing 2969 cases from 1981-2005. Results: The incidence of reported cases of WM was stable during the studied time period at 0.3 per 100,000. The median age at diagnosis was 73 (range 23-98). There were 1661 male cases of WM and 1038 female cases (incidence ratio of 1.6:1). There were 2435 Caucasian cases and 264 non-Caucasian cases (incidence ratio of 9.2:1). Median overall survival for the entire cohort was 65 months (95% CI, 61-69). Five-year overall survival was 52% (95% CI, 50-55%). There was a significant difference in survival for individuals age <60 years versus age ≥60 years with age-adjusted 5 year overall survivals of 78% (95% CI, 44-49%) and 47% (95% CI, 44-49%), p<0.0001, respectively. Gender and race had no impact on overall survival (p=0.23 and 0.13, respectively). There was no improvement in survival over the time period analyzed. The cohort of patients diagnosed in 1981-1995 had a 5-year overall survival of 50% (95% CI, 46-54%), and those diagnosed in 1996-2005 had a 5-year overall survival of 54% (95%CI, 51-57%), p=0.18. Conclusion: This survey represents the largest cohort of WM analyzed to date. Age was shown to be the sole predictor of overall survival. Furthermore, these results underscore the little therapeutic progress we have made for this disease considering the lack of improvement in overall survival over a quarter century. Disclosures: Vij: Otsuka Pharmaceuticals: Research Funding.

APA, Harvard, Vancouver, ISO, and other styles

22

Yu, James B., Danil V. Makarov, Richa Sharma, Richard E. Peschel, Alan W. Partin, and Cary P. Gross. "VALIDATING THE PARTIN TABLES USING THE NCI SEER DATABASE." Journal of Urology 181, no. 4S (April 2009): 170. http://dx.doi.org/10.1016/s0022-5347(09)60487-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Quinn, P. L., A. Alhatem, W. Xia, and R. J. Chokshi. "Pancreatic carcinosarcoma: A survival analysis of the seer database." HPB 22 (2020): S181—S182. http://dx.doi.org/10.1016/j.hpb.2020.04.742.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Ailawadhi, Sikander, Dongyun Yang, Gaurav Patel, Yin Zhang, Ibrahim T. Aldoss, Miriam Y. Kim, and Asher Chanan-Khan. "Outcome Disparities In Waldenstrom's Macroglobulinemia: A SEER Database Analysis." Blood 118, no. 21 (November 18, 2011): 845. http://dx.doi.org/10.1182/blood.v118.21.845.845.

Full text

Abstract:

Abstract Abstract 845 Background: Waldenstrom's macroglobulinemia (WM) is a relatively uncommon plasma cell disorder and most of previous literature is limited to small patient series. We have noted ethnic disparities in multiple myeloma, another plasma cell disorder. We undertook a large Surveillance Epidemiology and End Results (SEER) based analysis to describe outcome disparities in different subgroups of WM patients, with a focus on various ethnicities, so that therapeutic resources can be targeted more effectively. Methods: The SEER 17 Registry data (1973–2008) was utilized for patients with confirmed diagnosis of WM. To avoid bias of under representation of different ethnicities, analysis was restricted to patients with a diagnosis date of 1992 or later. Cases that received a diagnosis at death certificate or autopsy, no follow-up records, as well as lacking documentation on age at diagnosis, sex, or race/ethnicity were excluded. Cox proportional hazards models, adjusted for gender, age, race, year of diagnosis, marital status and stratified by SEER registries were used to evaluate associatio n between patient characteristics and survival. All statistical tests were two-sided and utilized the SAS software (v9.2) with a significance level of 0.05. Results: The final analysis included 2,840 WM patients (1,759 males; 62%, 1,081 females; 38%). The studied age-group cohorts included: 18–64 yrs (845; 30%), 65–74 yrs (795; 28%) and >75 yrs (1,200; 42%). Patients were stratified by race/ethnicity: White (2,471; 87%), African-American (AA) (102; 4%), Hispanic (133; 5%), Asian (129; 5%), and Native American (5; 0.1%). Patients were also stratified based on year of diagnosis (before or after 2002) to study the impact of certain novel agents (proteasome inhibitors, IMiDs) on WM treatment. There was a significant difference in the age at diagnosis of WM patients across different ethnicities, with AA the youngest (median 61.5 years) and Whites the oldest (median 73 years) subgroup (p<0.001). (Figure 1) Cause-specific mortality could not be evaluated due to variable documentation of reported causes of death for WM patients in the database. Survival analysis revealed that for all patients, females had better median overall survival (OS) than males (7.3 years vs. 6.2 years, HR 0.834; 95% CI 0.740, 0.939; p=0.003). Among the different age cohorts, patients with age ≥75 years had a significantly worse median OS (4.1 years) than those 65–74 year-old (7.3 years) or 18–64 year-old (10+ years) (p<0.001). Patients diagnosed after 2002 had a significantly better median OS (7.3 years) as compared to patients diagnosed previously (6.1 years) (p=0.002). Hispanics had the worst median OS (5 years) and Whites had the best median OS (6.8 years) across various ethnicities. In a multivariate model using gender, age, marital status, year of diagnosis and race, a significant interaction was noted between race, age and survival, with Hispanics having a significantly worse OS than Whites (HR 1.86; 95% CI 1.269, 2.726; p=0.003) (Figure 2). Conclusions: Studies of outcome disparities are important for evaluating disease characteristics and management needs of specific patient populations as well as optimal triaging of healthcare resources. We have performed the largest population-based analysis for WM including various ethnicities in the novel therapeutic agent era. We observed that AA patients had a significantly younger age at WM diagnosis. Older patients had worse OS across all ethnic subgroups and patients diagnosed after 2002 had a better OS suggesting an impact of novel therapeutic agents (e.g., proteasome inhibitors, IMiDs). Hispanic WM patients had the worst OS among all ethnicities. This survival difference was more significant and pronounced in patients >75 years. This suggests that the impact of race on survival is influenced by patient's age. These results will help in better understanding of various influences on disease biology and clinical behavior. Disclosures: No relevant conflicts of interest to declare.

APA, Harvard, Vancouver, ISO, and other styles

25

Wang, Samuel J., Rachel Emery, Clifton D. Fuller, Jong-Sung Kim, Dean F. Sittig, and Charles R. Thomas. "Conditional survival in gastric cancer: a SEER database analysis." Gastric Cancer 10, no. 3 (September 26, 2007): 153–58. http://dx.doi.org/10.1007/s10120-007-0424-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Ramsingh, G., P. Mehn, J. Luo, D. Morgensztern, and R. Vij. "A089 Solitary Plasmacytoma: A SEER Database Analysis of Survival." Clinical Lymphoma and Myeloma 9 (February 2009): S13—S14. http://dx.doi.org/10.1016/s1557-9190(11)70455-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Hansen, Tara M., Sachin Batra, Michael Lim, Gary L. Gallia, Peter C. Burger, Roberto Salvatori, Gary Wand, Alfredo Quinones-Hinojosa, Lawrence Kleinberg, and Kristin J. Redmond. "Invasive adenoma and pituitary carcinoma: a SEER database analysis." Neurosurgical Review 37, no. 2 (February 14, 2014): 279–86. http://dx.doi.org/10.1007/s10143-014-0525-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Amer, Kamil M., Murty Munn, Dominick Congiusta, John A. Abraham, and Atrayee Basu Mallick. "Survival and Prognosis of Chondrosarcoma Subtypes: SEER Database Analysis." Journal of Orthopaedic Research 38, no. 2 (September 22, 2019): 311–19. http://dx.doi.org/10.1002/jor.24463.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Lang, Julie E., Danielle E. Summers, Haiyan Cui, Joseph N. Carey, Rebecca K. Viscusi, Craig A. Hurst, Amy L. Waer, Michele L. B. Ley, Stephen F. Sener, and Aparna Vijayasekaran. "Trends in post-mastectomy reconstruction: A SEER database analysis." Journal of Surgical Oncology 108, no. 3 (July 16, 2013): 163–68. http://dx.doi.org/10.1002/jso.23365.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Orosco, Ryan K., Timon Hussain, Julia E. Noel, David C. Chang, Chrysoula Dosiou, Erik Mittra, Vasu Divi, and Lisa A. Orloff. "Radioactive iodine in differentiated thyroid cancer: a national database perspective." Endocrine-Related Cancer 26, no. 10 (October 2019): 795–802. http://dx.doi.org/10.1530/erc-19-0292.

Full text

Abstract:

Radioactive iodine (RAI) is a key component in the treatment of differentiated thyroid cancer. RAI has been recommended more selectively in recent years as guidelines evolve to reflect risks and utility in certain patient subsets. In this study we sought to evaluate the survival impact of radioactive iodine in specific thyroid cancer subgroups. Nationwide retrospective cohort study of patients using the National Cancer Database (NCDB) from 2004 to 2012 and Surveillance, Epidemiology, and End Results (SEER) database from 1992 to 2009 examining patients with differentiated thyroid cancer treated with or without RAI. Primary outcomes included all-cause mortality (NCDB and SEER), and cancer-specific mortality (SEER). Cox multivariate survival analyses were applied to each dataset, and in 135 patient subgroups based on clinical and non-clinical parameters. A total of 199,371 NCDB and 77,187 SEER patients were identified. RAI was associated with improved all-cause mortality (NCDB: RAI hazard ratio (HR) 0.55, P < 0.001; SEER: HR 0.64, P < 0.001); and cancer-specific mortality (SEER: HR 0.82, P = 0.029). Iodine therapy showed varied efficacy within each subgroup. Patients with high-risk disease experienced the greatest benefit in all-cause mortality, followed by intermediate-risk, then low-risk subgroups. Regarding cancer-specific mortality, radioactive iodine therapy was protective in high-risk patients, but did not achieve statistical significance in most intermediate-risk subgroups. Low-risk T1a subgroups demonstrated an increased likelihood of cancer-specific mortality with iodine therapy. The efficacy of RAI in patients with differentiated thyroid cancer varies by disease severity. A negative cancer-specific survival association was identified in patients with T1a disease. These findings warrant further evaluation with prospective studies.

APA, Harvard, Vancouver, ISO, and other styles

31

Lin, Chun Chieh, Katherine S. Virgo, Anthony S. Robbins, Ahmedin Jemal, and Elizabeth M. Ward. "Comparison of Comorbid Medical Conditions in the National Cancer Database and the SEER–Medicare Database." Annals of Surgical Oncology 23, no. 13 (August 17, 2016): 4139–48. http://dx.doi.org/10.1245/s10434-016-5508-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Bal, Ercan, Recep Öztürk, Burak Bahadır, Ömer Faruk Türkoğlu, and Mahmut Nedim Aytekin. "Epidemiological Analysis of Central Nervous System Teratomas in SEER Database." Journal of Ankara University Faculty of Medicine 73, no. 2 (August 1, 2020): 155–59. http://dx.doi.org/10.4274/atfm.galenos.2020.02997.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Man, Da, Jingjing Wu, Zhan Shen, and Xiaoyi Zhu. "Prognosis of patients with neuroendocrine tumor: a SEER database analysis." Cancer Management and Research Volume 10 (November 2018): 5629–38. http://dx.doi.org/10.2147/cmar.s174907.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Kukar, Moshim, Adrienne Groman, Usha Malhotra, Graham W. Warren, Paul Bogner, Chukwumere E. Nwogu, Todd L. Demmy, and Sai Yendamuri. "Small Cell Carcinoma of the Esophagus: A SEER Database Analysis." Annals of Surgical Oncology 20, no. 13 (August 14, 2013): 4239–44. http://dx.doi.org/10.1245/s10434-013-3167-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Khoury, John, Christopher Allen Willner, Bolanle Gbadamosi, Susanna Gaikazian, and Ishmael Jaiyesimi. "Demographics and Survival in Primary Effusion Lymphoma: SEER Database Analysis." Blood 132, Supplement 1 (November 29, 2018): 5397. http://dx.doi.org/10.1182/blood-2018-99-115473.

Full text

Abstract:

Abstract Background: Primary effusion lymphoma (PEL) is one of the least common of the AIDS-related lymphomas, accounting for less than 4% of cases. The optimal treatment for primary effusion lymphoma (PEL) remains unclear and there is a paucity of data regarding this neoplasm, which carries a uniformly poor prognosis. Antiretroviral therapy in addition to chemotherapy has shown to improve survival in a few small retrospective studies. Methods: Between 2002 and 2014, all cases of PEL were extracted from the population-based cancer registries of the Surveillance Epidemiology and End Results program (SEER). Instances of PEL were identified with the ICD-O-3 (9678) histological code. Frequency, demographics, and survival data were assessed using SPSS statistical software. Results: A total of 117 cases of PEL were identified. PEL was significantly more prevalent in men (89.7%) and in Caucasians (77.8%) with median age at diagnosis of 49 years. Median overall survival in the entire cohort was 6 months; CI, 3.7 to 8.2 months. Of all PEL cases, 62.4% received chemotherapy and 37.6% did not. Those who received chemotherapy had a median overall survival of 10 months vs less than one month when compared to subjects who did not receive chemotherapy (p = 0.002). PEL was the cause of death in 40.2% of the cases. PEL-specific median overall survival was markedly higher (29.000 months) than that of the entire cohort. Multivariable analysis demonstrated that age and race were not associated with mortality. Chemotherapy was associated with decreased mortality risk (HR, 0.45; CI, 0.28 -0.74; p = 0.002) Conclusions: In confirmation of previously published data, the highest incidence of PEL was found in Caucasian males. Subjects who received chemotherapy were found to have improved overall survival outcome. Other factors not related to PEL were associated with early mortality in this population. Disclosures No relevant conflicts of interest to declare.

APA, Harvard, Vancouver, ISO, and other styles

36

Bach, Peter B., Edward Guadagnoli, Deborah Schrag, Nicola Schussler, and Joan L. Warren. "Patient Demographic and Socioeconomic Characteristics in the SEER-Medicare Database." Medical Care 40, Supplement (August 2002): IV—19—IV—25. http://dx.doi.org/10.1097/00005650-200208001-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Komiya, Takefumi, Achuta K. Guddati, and Gerard Chaaya. "Overview of publications on lung cancer using the SEER database." Respiratory Investigation 56, no. 5 (September 2018): 424–26. http://dx.doi.org/10.1016/j.resinv.2018.06.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Bhaskarla, Amrit, Paul C. Tang, Terry Mashtare, Chukwumere E. Nwogu, Todd L. Demmy, Alex A. Adjei, Mary E. Reid, and Sai Yendamuri. "Analysis of Second Primary Lung Cancers in the SEER Database." Journal of Surgical Research 162, no. 1 (July 2010): 1–6. http://dx.doi.org/10.1016/j.jss.2009.12.030.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Blitzblau, R. C., J. B. Yu, L. D. Wilson, and K. B. Roberts. "Analysis of Gastric MALT Lymphomas Identified in the SEER Database." International Journal of Radiation Oncology*Biology*Physics 69, no. 3 (November 2007): S537—S538. http://dx.doi.org/10.1016/j.ijrobp.2007.07.1779.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Abdel-Rahman, Omar. "Squamous Cell Carcinoma of the Bladder: A SEER Database Analysis." Clinical Genitourinary Cancer 15, no. 3 (June 2017): e463-e468. http://dx.doi.org/10.1016/j.clgc.2016.10.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Florindez, Jorge, Juan Pablo Alderuccio, and Izidore Lossos. "Plasmablastic Lymphoma: Survival Analysis of a SEER Database (2010-2016)." Clinical Lymphoma Myeloma and Leukemia 19 (September 2019): S259—S260. http://dx.doi.org/10.1016/j.clml.2019.07.174.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Wang, Kewei, Fei Mei, Sisi Wu, and Zui Tan. "Hemangiopericytoma: Incidence, Treatment, and Prognosis Analysis Based on SEER Database." BioMed Research International 2020 (November 2, 2020): 1–11. http://dx.doi.org/10.1155/2020/2468320.

Full text

Abstract:

Background. Hemangiopericytomas are rare tumors derived from pericytes surrounding the blood vessels. The clinicopathological characteristics and prognosis of hemangiopericytoma patients remain mostly unknown. In this retrospective cohort study, we assessed the clinicopathological characteristics of hemangiopericytoma patients, as well as the clinical usefulness of different treatment modalities. Material and Methods. We collected the clinicopathological data (between 1975 and 2016) of hemangiopericytoma and hemangioendothelioma patients from the Surveillance, Epidemiology, and End Results (SEER) database. Incidence, treatment, and patient prognosis were assessed. Results. Data from 1474 patients were analyzed in our study cohort (hemangiopericytoma: n = 1243 ; hemangioendothelioma: n = 231 ). The incidence of hemangiopericytoma in 2016 was 0.060 per 100,000 individuals. The overall survival (OS) and cancer-specific survival (CSS) did not differ between patients with hemangioendothelioma and those with hemangiopericytoma ( P = 0.721 , P = 0.544 ). The tumor grade had no effect on the OS of hemangiopericytoma patients. Multivariate analysis revealed the clinical usefulness of surgery in hemangiopericytoma patients ( HR = 0.15 , 95% confidence interval: 0.05-0.41, P < 0.001 ). In contrast, radiotherapy did not improve OS ( P = 0.497 ) or CSS ( P = 0.584 ), and chemotherapy worsened patient survival ( P < 0.001 ). Additionally, the combination of surgery and radiotherapy had a similar effect with surgery alone on hemangiopericytoma patient survival (OS: P = 0.900 ; CSS: P = 0.156 ). Surgery plus chemotherapy provided a worse clinical benefit than surgery alone ( P < 0.001 ). Conclusions. Our findings suggested that hemangiopericytoma had a similar prognosis with hemangioendothelioma. Surgery was the only effective treatment that provided survival benefits in hemangiopericytoma patients, while the clinical usefulness of adjuvant chemotherapy or radiotherapy was limited.

APA, Harvard, Vancouver, ISO, and other styles

43

Salami, A. C., and A. R. T. Joshi. "Improving outcomes of cholangiocarcinoma: an analysis of the seer database." HPB 20 (March 2018): S62. http://dx.doi.org/10.1016/j.hpb.2018.02.282.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Brar, Gagandeep, Tim F. Greten, Barry I. Graubard, Timothy S. McNeel, Jessica L. Petrick, Katherine A. McGlynn, and Sean F. Altekruse. "Hepatocellular Carcinoma Survival by Etiology: A SEER‐Medicare Database Analysis." Hepatology Communications 4, no. 10 (August 9, 2020): 1541–51. http://dx.doi.org/10.1002/hep4.1564.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Liang, Wenhua, Jiaxi He, Yaxing Shen, Jianfei Shen, Qihua He, Jianrong Zhang, Gening Jiang, et al. "Impact of Examined Lymph Node Count on Precise Staging and Long-Term Survival of Resected Non–Small-Cell Lung Cancer: A Population Study of the US SEER Database and a Chinese Multi-Institutional Registry." Journal of Clinical Oncology 35, no. 11 (April 10, 2017): 1162–70. http://dx.doi.org/10.1200/jco.2016.67.5140.

Full text

Abstract:

Purpose We investigated the correlation between the number of examined lymph nodes (ELNs) and correct staging and long-term survival in non–small-cell lung cancer (NSCLC) by using large databases and determined the minimal threshold for the ELN count. Methods Data from a Chinese multi-institutional registry and the US SEER database on stage I to IIIA resected NSCLC (2001 to 2008) were analyzed for the relationship between the ELN count and stage migration and overall survival (OS) by using multivariable models. The series of the mean positive LNs, odds ratios (ORs), and hazard ratios (HRs) were fitted with a LOWESS smoother, and the structural break points were determined by Chow test. The selected cut point was validated with the SEER 2009 cohort. Results Although the distribution of ELN count differed between the Chinese registry (n = 5,706) and the SEER database (n = 38,806; median, 15 versus seven, respectively), both cohorts exhibited significantly proportional increases from N0 to N1 and N2 disease (SEER OR, 1.038; China OR, 1.012; both P < .001) and serial improvements in OS (N0 disease: SEER HR, 0.986; China HR, 0.981; both P < .001; N1 and N2 disease: SEER HR, 0.989; China HR, 0.984; both P < .001) as the ELN count increased after controlling for confounders. Cut point analysis showed a threshold ELN count of 16 in patients with declared node-negative disease, which were examined in the derivation cohorts (SEER 2001 to 2008 HR, 0.830; China HR, 0.738) and validated in the SEER 2009 cohort (HR, 0.837). Conclusion A greater number of ELNs is associated with more-accurate node staging and better long-term survival of resected NSCLC. We recommend 16 ELNs as the cut point for evaluating the quality of LN examination or prognostic stratification postoperatively for patients with declared node-negative disease.

APA, Harvard, Vancouver, ISO, and other styles

46

Sun, Xuheng, Yingbin Liu, and Yijun WANG. "Comparison of clinical pathological features, surgical treatments and prognosis of Gallbladder Neuroendocrine Neoplasms between Chinese and American population: Based on a nationwide multicenter study and SEER database." Journal of Clinical Oncology 40, no. 16_suppl (June 1, 2022): e16119-e16119. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e16119.

Full text

Abstract:

e16119 Background: Gallbladder Neuroendocrine Neoplasm (GB-NEN) is an extremely rare type of gallbladder neoplasms and its characteristics and prognosis varies widely. The focus of this study was to analyze and compare the clinical pathological features, surgical treatments and prognosis of patients with GB-NEN between Chinese and American population. Methods: The Chinese Research Group of Gallbladder Cancer (CRGGC) study is a multicenter retrospective registry cohort study reviewing the electronic medical records from 76 tertiary and secondary hospitals across 28 provinces in China. Patients diagnosed with GB-NEN according to the 2019 WHO classification between 2010 and 2017 were assembled from CRGGC study and National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database. Chi-square test for categorical variables and the overall survival outcomes were analyzed by the Kaplan–Meier method in the two groups before and after a propensity score matching (PSM) with 1:1 ratio. Results: In this study, we assembled totally 84 patients from CRGGC study and there were 217 patients with GB-NEN diagnosed during the same period from National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database. After the PSM using sex, age, American Joint Committee on Cancer stage 7th Edition, liver invasion status and types of surgical treatment, 19 pairs of patients were included. Chinese patients from the CRGGC with GB-NENs presents more liver invasion (c²= 22.621, P = 0.000), higher diagnosed age (c²= 37.313, P = 0.000) and cancer stage (c²= 13.298, P = 0.021) totally than those from the SEER database. Radical surgical treatments were performed in 51(60.714%) and 96(44.240%) patients among patients from the CRGGC study and the SEER database respectively and the surgical treatment model shows a difference between these two groups (c²= 85.729, P = 0.000). Compared with propensity score matched American patients with GB-NENs from SEER database, Chinese patients from the CRGGC study had similar overall survival(c²= 0.480, P = 0.489) instead of longer overall survival than patients from the SEER database before PSM(c²= 6.408, P = 0.011). Conclusions: Chinese and American patients with GB-NEN form the CRGGC study and the SEER database present no difference in overall survival after PSM. However, heterogeneity of pathological features, surgical treatments between those groups of GB-NEN patients prompt that different methods could be referred for the improvement in the survival of GB-NEN patients.

APA, Harvard, Vancouver, ISO, and other styles

47

Shewade, Ashwini, Adam J. Olszewski, Nelson Pace, Andy Surinach, Gila Sellam, Lars Mueller, and Carol O'Hear. "Unmet Medical Need Among Elderly Patients with Previously Untreated DLBCL Characterized Using Real-World Data in the United States." Blood 136, Supplement 1 (November 5, 2020): 6–8. http://dx.doi.org/10.1182/blood-2020-136271.

Full text

Abstract:

Introduction: Diffuse large B-cell lymphoma (DLBCL) is a significant source of cancer morbidity and mortality. More than half of all newly diagnosed patients are older than 65 years, among whom the 5-year relative survival rate is 54% (SEER 2020). Prior research has shown that not all elderly patients (≥80 years old) receive R-CHOP or mini-R-CHOP regimens as the first line of therapy (LoT); those who do not may have suboptimal outcomes (Williams, et al. Cancer 2015; Hamlin, et al. Oncologist 2014; Juul, et al. Eur J Cancer 2018). This study leverages two real-world data (RWD) sources, Flatiron Health (FH) electronic health record-derived de-identified database and SEER-Medicare (SEER-M) to characterize elderly patients with DLBCL (including observed treatment patterns), summarize overall survival (OS) outcomes, and identify unmet medical needs in this population. Methods: RWD from FH included patients with a DLBCL diagnosis on or after January 1, 2011, with follow-up until May 31, 2020. The SEER-M database is a linkage of two population-based RWD sources: the SEER Cancer Registry and Medicare claims database. RWD from SEER-M for this study included patients with a DLBCL diagnosis between January 1, 2011 and December 31, 2015, with follow-up until December 31, 2016. All fee-for-service Medicare enrollees in SEER-M had to have complete claims. RWD for basic demographics, treatments and outcomes were analyzed from both datasets; FH's database included data on certain clinical characteristics including granularity for dosing data when available, in comparison to SEER-M. This descriptive analysis included patients who were aged ≥80 years at diagnosis. Among patients in the FH database who received R-CHOP as first LoT and had available dosing data, those who received <80% of standard full doses for cyclophosphamide (750mg/m2) and doxorubicin (50mg/m2) at first administration were classified as "reduced-dose" R-CHOP. OS data were summarized using an unadjusted Kaplan-Meier survival function and 95% confidence intervals (CI). Results: The study included 725 patients from the FH database and 2613 patients from the SEER-M database; patient characteristics and outcomes were generally consistent between the two datasets. In total, 16% and 35% of the elderly patients had no record of systemic treatment in FH and SEER-M respectively (Table). More than half of the treated patients received R-CHOP in the first LoT (63% and 53% in FH and SEER-M, respectively); other patients received attenuated regimens, including rituximab plus bendamustine (R-Benda), rituximab plus cyclophosphamide, vincristine and prednisolone (R-CVP), and rituximab (R) monotherapy. Patients who received R-CHOP in the first LoT had numerically longer median OS (Flatiron: 55.0 months [95% CI: 41.8-NA]; SEER-M: 50.7 months [95% CI: 45.9-62.9]) compared with those who received other regimens (Figure A, B). Untreated patients had a median survival of 3.1 months (95% CI: 2.3-5.2) in the Flatiron dataset and 2.0 months (95% CI: 1.8-2.2) in the SEER-M dataset. Among those who received R-CHOP and with available dosing data, 51% received reduced-dose R-CHOP in the first LoT and OS appeared shorter than for patients who received full-dose R-CHOP (Figure C). Conclusions: Despite differences between the databases, RWD in FH and SEER-M both demonstrate considerable variation in the regimens received by elderly DLBCL patients, with 16-35% receiving no treatment and >50% receiving attenuated regimens including reduced-dose R-CHOP. Patients receiving regimens other than R-CHOP had a numerically lower survival probability compared with the standard of care (SoC) R-CHOP/reduced-dose R-CHOP. These data show a high unmet medical need among elderly patients with DLBCL who may not be able to tolerate immunochemotherapy regimens that have been evaluated in trials for a carefully selected patient population. Further research will aim to assess prognostic factors at the time of treatment initiation, as well as gather information on comorbidities and other factors that may prevent elderly patients from receiving SoC R-CHOP; these patients may be candidates for better-tolerated novel approaches. Disclosures Shewade: Genentech, Inc.: Current Employment. Olszewski:TG Therapeutics: Research Funding; Adaptive Biotechnologies: Research Funding; Genentech, Inc.: Research Funding; Spectrum Pharmaceuticals: Research Funding. Pace:Genentech, Inc.: Current Employment; Exponent: Ended employment in the past 24 months; Prior employer was a consulting firm. No expert testimony given. No relevant consulting work done.: Consultancy. Surinach:Seattle Genetics: Research Funding. Sellam:F. Hoffmann-La Roche: Current Employment. Mueller:Genentech, Inc.: Current Employment, Ended employment in the past 24 months; F. Hoffmann-La Roche: Current equity holder in publicly-traded company. O'Hear:Genentech, Inc.: Current Employment; F. Hoffmann-La Roche: Current equity holder in publicly-traded company.

APA, Harvard, Vancouver, ISO, and other styles

48

张, 云波. "Pathological Characteristics and Prognosis of Esophageal Cancer Based on SEER Database." Advances in Clinical Medicine 10, no. 07 (2020): 1500–1510. http://dx.doi.org/10.12677/acm.2020.107226.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Ghimire, Krishna Bilas, Barsha Nepal, and Binay Kumar Shah. "Analysis of second primary cancers in gastroinstestinal stromal tumor patients using SEER database." Journal of Clinical Oncology 31, no. 4_suppl (February 1, 2013): 327. http://dx.doi.org/10.1200/jco.2013.31.4_suppl.327.

Full text

Abstract:

327 Background: Development of second primary cancers among gastrointestinal stromal tumor (GIST) patients is not very well studied. This study was conducted to evaluate second primary malignancies in GIST patients using U.S. Surveillance, Epidemiology, and End Results (SEER) cancer registry database. Methods: We analyzed the Surveillance, Epidemiology, and End Results (SEER Stat) database: Incidence - SEER 13 Regs Research Data, Nov 2011 Sub, Vintage 2009 Pops (1992-2009) using MP-SIR session. We analysed secondary cancer rate among adult GIST patients during the period 1992-2009. We also compared the risk of secondary malignancies in pre- (1992-2001) to post-imatinib (2002-2009) eras. We used SEER MP-SIR session and Graph pad scientific software to calculate p value. Results: There were 2,436 (693 in pre-imatinib era and 1,743 in post-imatinib era) GIST patients reported during 1992-2009 period in SEER database. Among them, 163 GIST patients developed second primary malignancy, which is significantly higher than expected in general population, with observed/expected (O/E) ratio: 1.31, p value = <0.05, (95% CI: 1.11-1.52) and excess risk of 39.76 per 10,000 population. The total number of second primary cancers in GIST in pre- and post-imatinib eras were 69 and 94, p value = <0.0001 with observed/expected (O/E) ratio of 29.18 and 48.22 respectively. The total number of second primary solid tumors in pre- and post-imatinib era was: 59 and 84, p value=0.0008 and O/E ratio: 20.18 vs 43.32 respectively. Conclusions: This study showed overall increased risk of second primary malignancies among GIST patients as compared to general population. There was significantly increased risk of second primary malignancies, especially solid tumors in post-imatinib era. [Table: see text]

APA, Harvard, Vancouver, ISO, and other styles

50

Gore, Mitchell R. "A Population-Based Analysis of Treatment, Survival, and Demographics in Otologic Malignancies." European Journal of Medical and Health Sciences 4, no. 5 (October 19, 2022): 95–99. http://dx.doi.org/10.24018/ejmed.2022.4.5.1504.

Full text

Abstract:

Introduction: Otologic (external ear, middle ear, and temporal bone) malignancies are relatively uncommon tumors. Their location adjacent to vital structures such as the carotid artery, jugular vein, otic capsule, and temporal lobe makes treatment potentially challenging. Objective: The purpose of this study was to examine overall survival outcomes in patients with otologic malignancies obtained via a population-based cancer database. Methods: A search of the Surveillance, Epidemiology, and End Results (SEER) database was used to identify patients treated for external ear, middle ear, and temporal bone malignancies from 1973-2018. Demographic and overall survival data were compiled and analyzed using Kaplan-Meier and logistic regression analysis. Results: The SEER database identified 9317 patients with otologic malignancies. Multivariate analysis of the SEER data showed that age, race, sex, subsite, histopathological type, overall stage, T, N, and M stage, and treatment type significantly affected overall survival. Conclusion: This study examined data on demographics, treatment, and survival of patients with otologic malignancies utilizing the population-based SEER database. Overall stage and T, N, and M stages, patient age, sex, race, treatment type, and histopathological type all appear to significantly impact overall survival. Patients treated with surgery as part of their treatment regimen appeared to have higher 5-year overall survival than patients treated nonsurgically.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!